Strides Pharma Science is currently trading at Rs. 423.00, up by 11.10 points or 2.69% from its previous closing of Rs. 411.90 on the BSE.
The scrip opened at Rs. 426.50 and has touched a high and low of Rs. 426.50 and Rs. 420.50 respectively. So far 5923 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 1000.00 on 08-Jan-2021 and a 52 week low of Rs. 403.55 on 20-Dec-2021.
Last one week high and low of the scrip stood at Rs. 497.35 and Rs. 403.55 respectively. The current market cap of the company is Rs. 3698.15 crore.
The promoters holding in the company stood at 29.60%, while Institutions and Non-Institutions held 45.40% and 25.00% respectively.
Strides Pharma Science’s biotech division — Stelis Biopharma (Stelis) has commissioned its large-scale fully integrated vaccine manufacturing facility at Bengaluru, India. The facility was successfully inspected by the Central Drugs Standard Control Organization (CDSCO). Stelis has also received an initial Export No Objection Certificate (NOC) from CDSCO to export up to 50 million doses of the Sputnik Light vaccine.
Stelis’ greenfield vaccine facility was built in a record time of less than 200 days with a best in class design and modularity to cater to several vaccine formats. It is also one of the largest viral vector manufacturing sites with a bespoke design for producing the Russian Sputnik Vaccine.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.